20 (AIDX) Cash from Financing Activities (2025 - 2026)
20's (AIDX) quarterly Cash from Financing Activities came in at $4.5 million in Q1 2026, up 1610.55% YoY from $262338.0 in Q1 2025, and up 1610.55% on a QoQ basis from $262338.0 in Q1 2025.
20 (AIDX) Cash from Financing Activities (2025 - 2026) Analysis & Trends
20 (AIDX) has 2 years of Cash from Financing Activities data on file, last reported at $4.5 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.44 Bn | 193.84 Bn | 7.27 Bn | -3.52 Bn |
| 2 | Stryker | 127.32 Bn | 123.85 Bn | 4.50 Bn | -95.00 Mn |
| 3 | Medtronic | 118.87 Bn | 109.65 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 73.47 Bn | 72.93 Bn | 3.85 Bn | -410.00 Mn |
| 5 | Edwards Lifesciences | 51.90 Bn | 47.65 Bn | 1.35 Bn | -300,000.00 |
| 6 | Dexcom | 34.30 Bn | 32.36 Bn | 830.00 Mn | -607.30 Mn |
| 7 | GE HealthCare Technologies | 33.74 Bn | 31.63 Bn | 2.18 Bn | -236.00 Mn |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | -1.34 Bn |
| 9 | Steris | 23.05 Bn | 22.56 Bn | 684.20 Mn | -213.50 Mn |
| 10 | 20 | 5.55 Mn | 1.00 Mn | 304,727.00 | 940,001.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.49 Mn |
| Mar 31, 2026 | 4.49 Mn |
| Mar 31, 2025 | 262,338.00 |
| Mar 31, 2025 | 262,338.00 |